Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) Profit After Tax (2022 - 2025)

Historic Profit After Tax for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$51.2 million.

  • ARS Pharmaceuticals' Profit After Tax fell 16741.43% to -$51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$80.0 million, marking a year-over-year decrease of 6300.1%. This contributed to the annual value of $8.0 million for FY2024, which is 11471.17% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its Profit After Tax stood at -$51.2 million for Q3 2025, which was down 16741.43% from -$44.9 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' Profit After Tax peaked at $49.9 million during Q4 2024, and registered a low of -$51.2 million during Q3 2025.
  • Its 4-year average for Profit After Tax is -$14.1 million, with a median of -$14.4 million in 2022.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Profit After Tax soared by 79662.39% in 2024, and later tumbled by 25860.5% in 2025.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' Profit After Tax stood at -$14.4 million in 2022, then surged by 50.32% to -$7.2 million in 2023, then surged by 796.62% to $49.9 million in 2024, then tumbled by 202.44% to -$51.2 million in 2025.
  • Its Profit After Tax stands at -$51.2 million for Q3 2025, versus -$44.9 million for Q2 2025 and -$33.9 million for Q1 2025.